| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Neoplasms | 15 | 2024 | 253 | 7.050 |
Why?
|
| Ovarian Neoplasms | 12 | 2023 | 779 | 3.720 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 6 | 2023 | 19 | 3.240 |
Why?
|
| Biomarkers, Tumor | 16 | 2024 | 1564 | 3.190 |
Why?
|
| Endometrial Neoplasms | 7 | 2023 | 209 | 2.880 |
Why?
|
| Carcinoma, Endometrioid | 6 | 2023 | 49 | 2.630 |
Why?
|
| Neoplasms, Muscle Tissue | 4 | 2024 | 13 | 2.560 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 3 | 2021 | 9 | 2.080 |
Why?
|
| Immunohistochemistry | 15 | 2024 | 1807 | 2.070 |
Why?
|
| DNA Mismatch Repair | 4 | 2023 | 58 | 1.520 |
Why?
|
| Genital Neoplasms, Female | 3 | 2022 | 110 | 1.490 |
Why?
|
| Adenocarcinoma, Clear Cell | 4 | 2022 | 61 | 1.460 |
Why?
|
| Myofibroma | 2 | 2020 | 4 | 1.290 |
Why?
|
| Female | 47 | 2024 | 47284 | 1.250 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2022 | 47 | 1.240 |
Why?
|
| Adenoma | 2 | 2022 | 251 | 1.230 |
Why?
|
| Adnexal Diseases | 2 | 2019 | 16 | 1.130 |
Why?
|
| Carcinoma | 3 | 2022 | 438 | 1.120 |
Why?
|
| Peutz-Jeghers Syndrome | 2 | 2024 | 9 | 1.120 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 3 | 2021 | 53 | 1.070 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2016 | 23 | 1.010 |
Why?
|
| Sarcoma, Endometrial Stromal | 2 | 2023 | 8 | 1.000 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2022 | 6 | 0.950 |
Why?
|
| Teratoma | 2 | 2023 | 53 | 0.930 |
Why?
|
| Endometrial Stromal Tumors | 2 | 2023 | 5 | 0.930 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 52 | 0.920 |
Why?
|
| Nuclear Receptor Coactivator 2 | 2 | 2021 | 16 | 0.900 |
Why?
|
| Humans | 48 | 2024 | 91235 | 0.870 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2024 | 105 | 0.860 |
Why?
|
| Adenocarcinoma | 2 | 2022 | 1184 | 0.850 |
Why?
|
| Leiomyoma | 2 | 2017 | 204 | 0.820 |
Why?
|
| Broad Ligament | 1 | 2022 | 1 | 0.800 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2022 | 2 | 0.800 |
Why?
|
| Ribonuclease III | 2 | 2022 | 16 | 0.790 |
Why?
|
| Middle Aged | 24 | 2024 | 26618 | 0.790 |
Why?
|
| Adult | 22 | 2024 | 27215 | 0.770 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2022 | 65 | 0.760 |
Why?
|
| Leiomyosarcoma | 1 | 2022 | 46 | 0.760 |
Why?
|
| Krukenberg Tumor | 2 | 2018 | 3 | 0.750 |
Why?
|
| Smooth Muscle Tumor | 1 | 2021 | 5 | 0.750 |
Why?
|
| Fibronectins | 1 | 2021 | 102 | 0.720 |
Why?
|
| Angiofibroma | 1 | 2020 | 4 | 0.710 |
Why?
|
| Vulvar Neoplasms | 1 | 2020 | 19 | 0.710 |
Why?
|
| Myxoma | 1 | 2020 | 30 | 0.700 |
Why?
|
| Glioma | 1 | 2023 | 295 | 0.700 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2018 | 356 | 0.700 |
Why?
|
| Polyps | 1 | 2020 | 29 | 0.690 |
Why?
|
| DNA-Binding Proteins | 5 | 2023 | 1248 | 0.690 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2019 | 33 | 0.670 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 307 | 0.670 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 11 | 0.660 |
Why?
|
| Diagnosis, Differential | 8 | 2024 | 1610 | 0.660 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 129 | 0.660 |
Why?
|
| Aged | 16 | 2024 | 19604 | 0.650 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 72 | 0.630 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2018 | 9 | 0.620 |
Why?
|
| Epithelioid Cells | 1 | 2018 | 13 | 0.620 |
Why?
|
| Fumarate Hydratase | 1 | 2017 | 6 | 0.570 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 668 | 0.570 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 160 | 0.550 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 3033 | 0.530 |
Why?
|
| Progestins | 1 | 2016 | 22 | 0.520 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 55 | 0.510 |
Why?
|
| Nuclear Proteins | 2 | 2021 | 731 | 0.500 |
Why?
|
| Giant Cell Tumors | 1 | 2015 | 3 | 0.500 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 3 | 2023 | 24 | 0.500 |
Why?
|
| MutL Protein Homolog 1 | 3 | 2023 | 35 | 0.500 |
Why?
|
| Ovary | 2 | 2021 | 263 | 0.490 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2015 | 28 | 0.490 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 155 | 0.490 |
Why?
|
| Ataxia Telangiectasia | 1 | 2015 | 11 | 0.490 |
Why?
|
| Premenopause | 1 | 2015 | 57 | 0.480 |
Why?
|
| Parotid Gland | 1 | 2015 | 30 | 0.470 |
Why?
|
| Young Adult | 7 | 2024 | 6522 | 0.470 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 55 | 0.460 |
Why?
|
| Postmenopause | 1 | 2015 | 102 | 0.460 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 120 | 0.460 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 316 | 0.450 |
Why?
|
| Testosterone | 1 | 2015 | 272 | 0.450 |
Why?
|
| Skin Diseases | 1 | 2015 | 174 | 0.440 |
Why?
|
| Prognosis | 8 | 2022 | 3829 | 0.430 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 379 | 0.420 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 1748 | 0.380 |
Why?
|
| Sarcoma | 2 | 2024 | 217 | 0.360 |
Why?
|
| Adolescent | 5 | 2024 | 9435 | 0.340 |
Why?
|
| Tumor Burden | 2 | 2024 | 312 | 0.340 |
Why?
|
| Child | 4 | 2024 | 7291 | 0.340 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6844 | 0.340 |
Why?
|
| Urethral Stricture | 2 | 2019 | 14 | 0.330 |
Why?
|
| Gene Fusion | 2 | 2020 | 41 | 0.330 |
Why?
|
| Mutation | 4 | 2021 | 4210 | 0.320 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 300 | 0.310 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 177 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1378 | 0.280 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 277 | 0.260 |
Why?
|
| Biopsy | 3 | 2019 | 1195 | 0.250 |
Why?
|
| Cervix Uteri | 3 | 2022 | 71 | 0.230 |
Why?
|
| Oncogene Fusion | 2 | 2021 | 9 | 0.230 |
Why?
|
| Tissue Array Analysis | 2 | 2021 | 127 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 853 | 0.210 |
Why?
|
| Necrosis | 1 | 2023 | 210 | 0.210 |
Why?
|
| Incidence | 2 | 2019 | 1599 | 0.210 |
Why?
|
| Lichen Sclerosus et Atrophicus | 2 | 2019 | 7 | 0.210 |
Why?
|
| Gene Deletion | 1 | 2024 | 345 | 0.210 |
Why?
|
| Adenosarcoma | 1 | 2022 | 3 | 0.200 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 20 | 0.200 |
Why?
|
| Wolffian Ducts | 1 | 2022 | 7 | 0.200 |
Why?
|
| Phenotype | 2 | 2019 | 2489 | 0.200 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2022 | 5 | 0.200 |
Why?
|
| Endometrial Hyperplasia | 1 | 2022 | 11 | 0.200 |
Why?
|
| Hemorrhage | 1 | 2023 | 289 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 45 | 0.190 |
Why?
|
| Cystadenoma, Papillary | 1 | 2021 | 9 | 0.190 |
Why?
|
| SMARCB1 Protein | 1 | 2021 | 13 | 0.180 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2021 | 24 | 0.180 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2021 | 20 | 0.180 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2020 | 4 | 0.180 |
Why?
|
| Urogenital Neoplasms | 1 | 2021 | 24 | 0.180 |
Why?
|
| Genitalia, Female | 1 | 2020 | 25 | 0.180 |
Why?
|
| Vulva | 1 | 2020 | 23 | 0.180 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 134 | 0.180 |
Why?
|
| DNA Helicases | 1 | 2021 | 85 | 0.170 |
Why?
|
| Immunophenotyping | 1 | 2020 | 218 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 2383 | 0.170 |
Why?
|
| Papillomaviridae | 2 | 2022 | 168 | 0.170 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2019 | 15 | 0.170 |
Why?
|
| Gene Dosage | 1 | 2019 | 210 | 0.160 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 2024 | 0.150 |
Why?
|
| Urethra | 1 | 2019 | 116 | 0.150 |
Why?
|
| Pregnancy | 2 | 2016 | 3086 | 0.150 |
Why?
|
| Mitosis | 1 | 2018 | 152 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 333 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2023 | 9401 | 0.140 |
Why?
|
| Genomics | 1 | 2023 | 804 | 0.140 |
Why?
|
| Boston | 1 | 2016 | 37 | 0.130 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2016 | 133 | 0.130 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2016 | 34 | 0.130 |
Why?
|
| Salpingectomy | 1 | 2015 | 3 | 0.130 |
Why?
|
| Penicillamine | 1 | 2015 | 12 | 0.130 |
Why?
|
| Voice Disorders | 1 | 2015 | 7 | 0.130 |
Why?
|
| California | 1 | 2016 | 152 | 0.130 |
Why?
|
| Elastic Tissue | 1 | 2015 | 18 | 0.130 |
Why?
|
| Alopecia | 1 | 2015 | 34 | 0.130 |
Why?
|
| Luteinization | 1 | 2015 | 1 | 0.130 |
Why?
|
| Hirsutism | 1 | 2015 | 61 | 0.120 |
Why?
|
| Ovariectomy | 1 | 2015 | 83 | 0.120 |
Why?
|
| Inflammation | 1 | 2021 | 1003 | 0.120 |
Why?
|
| Hyperplasia | 1 | 2015 | 153 | 0.120 |
Why?
|
| Septum of Brain | 2 | 2005 | 2 | 0.120 |
Why?
|
| Stromal Cells | 1 | 2016 | 151 | 0.120 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 60 | 0.120 |
Why?
|
| Scleroderma, Systemic | 1 | 2015 | 56 | 0.120 |
Why?
|
| Ovarian Diseases | 1 | 2015 | 32 | 0.120 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 16 | 0.120 |
Why?
|
| Fibroma | 1 | 2015 | 33 | 0.120 |
Why?
|
| Parasympathetic Nervous System | 2 | 2005 | 36 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 137 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2015 | 110 | 0.120 |
Why?
|
| Estradiol | 1 | 2015 | 250 | 0.120 |
Why?
|
| Endometriosis | 1 | 2015 | 59 | 0.120 |
Why?
|
| Extremities | 1 | 2015 | 178 | 0.110 |
Why?
|
| Risk Factors | 1 | 2024 | 5609 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 345 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2021 | 1672 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2788 | 0.100 |
Why?
|
| Insulin | 1 | 2015 | 1162 | 0.090 |
Why?
|
| Axotomy | 2 | 2005 | 8 | 0.080 |
Why?
|
| Time Factors | 1 | 2016 | 5385 | 0.070 |
Why?
|
| Capsid Proteins | 1 | 2005 | 32 | 0.060 |
Why?
|
| Nerve Growth Factors | 1 | 2005 | 63 | 0.060 |
Why?
|
| Polyethyleneimine | 1 | 2004 | 7 | 0.060 |
Why?
|
| Nerve Growth Factor | 1 | 2004 | 18 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 2551 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2005 | 448 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 153 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 3723 | 0.050 |
Why?
|
| Male | 5 | 2021 | 43375 | 0.050 |
Why?
|
| Co-Repressor Proteins | 1 | 2023 | 25 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1822 | 0.050 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 19 | 0.050 |
Why?
|
| Uterus | 1 | 2023 | 222 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2022 | 532 | 0.040 |
Why?
|
| beta Catenin | 1 | 2022 | 267 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 2021 | 511 | 0.040 |
Why?
|
| Point Mutation | 1 | 2021 | 246 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2023 | 430 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 95 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 874 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 494 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2022 | 1883 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 390 | 0.030 |
Why?
|
| Reoperation | 1 | 2019 | 611 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2016 | 38 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 1171 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 2016 | 70 | 0.030 |
Why?
|
| Neurons | 1 | 2004 | 1599 | 0.030 |
Why?
|
| Vagina | 1 | 2016 | 176 | 0.030 |
Why?
|
| Stereotaxic Techniques | 2 | 2005 | 80 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2022 | 2344 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 2 | 2005 | 308 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1473 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 1230 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 4374 | 0.020 |
Why?
|
| Rats | 2 | 2005 | 4060 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 8429 | 0.020 |
Why?
|
| Fornix, Brain | 1 | 2005 | 2 | 0.020 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2005 | 23 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2005 | 275 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 375 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2004 | 71 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2004 | 144 | 0.010 |
Why?
|
| Transgenes | 1 | 2004 | 185 | 0.010 |
Why?
|
| Animals | 2 | 2005 | 27852 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 12029 | 0.010 |
Why?
|